[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350428-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350428-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","intratumoral-c3arc5ar1-antagonists-imbedded-in-an-in-situ-forming-implant-can-robustly-suppress-solid-tumors","Intratumoral C3ar/C5ar1 Antagonists Imbedded in an In Situ Forming Implant Can Robustly Suppress Solid Tumors","","Solid tumors often develop a “cold” immunosuppressive tumor microenvironment (TME), limiting CAR T cell activity and conventional treatments. Intratumoral delivery of C3a/C5a receptor 1 (C3ar/C5ar1) pharmaceutical antagonists using an in situ forming implant (ISFI) markedly suppresses tumors. Antagonizing autocrine signaling across eight human and murine cancers shows universal anti-mitotic and pro-apoptotic effects in vitro, and strong growth repression in vivo, achieving near-complete elimination with slow-release PLGA.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/intratumoral-c3arc5ar1-antagonists-imbedded-in-an-in-situ-forming-implant-can-robustly-suppress-solid-tumors/350428/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/intratumoral-c3arc5ar1-antagonists-imbedded-in-an-in-situ-forming-implant-can-robustly-suppress-solid-tumors/350428.png","ImageObject",300,407,{"name":42,"@type":43},"Dipper","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are solid tumors difficult to treat with CAR T cells or conventional therapies?","Question",{"text":63,"@type":64},"Solid tumors typically expand within a “cold” immunosuppressive tumor microenvironment (TME), which resists killing by CAR T cells or conventional therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is the main therapeutic strategy tested in the study?",{"text":68,"@type":64},"The study tests intratumoral injection of C3ar/C5ar1 antagonists delivered via an in situ forming implant (ISFI), aiming for sustained blockade in the tumor and TME.",{"name":70,"@type":61,"acceptedAnswer":71},"What biological processes are affected by intratumoral C3ar/C5ar1 blockade?",{"text":72,"@type":64},"The focused blockade disrupts solid cancer growth by jointly repressing cancer cell viability and growth, tumor-associated angiogenesis, and myeloid-derived suppressor cell (MDSC) recruitment.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350428,1790623418,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \nIntratumoral C3ar/C5ar1 Antagonists Imbedded in an In Situ Forming Implant Can Robustly Suppress Solid Tumors  \nYoung A Choi 1,†, Ryan Konrad 1,†, Elliot S. Pohlmann 1,2, Eric Abenojar 2, Agata Exner 2 and M. Edward Medof 1, *  \nAcademic Editor: Alexander E. Kalyuzhny  \nReceived: 5 December 2025  \nRevised: 31 December 2025  \nAccepted: 4 March 2026  \nPublished: 25 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Institute of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA; [young.choi@advocatehealth.org](young.choi@advocatehealth.org) (Y.A.C.); [ryan.konrad@case.edu](ryan.konrad@case.edu) (R.K.); [elliot.pohlmann@case.edu](elliot.pohlmann@case.edu) (E.S.P.)  \n2 Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA 24016, USA; [eric.abenojar@case.edu](eric.abenojar@case.edu) (E.A.); [agata.exner@case.edu](agata.exner@case.edu) (A.E.)  \n* Correspondence: [edward.medof@case.edu](edward.medof@case.edu)[ ](edward.medof@case.edu)† These authors contributed equally to the work.  \nAbstract  \nSolid tumors typically expand in a “cold” immunosuppressive tumor microenvironment (TME) and resist killing by CAR T cells or conventional therapy. Herein, we show that intratumoral injection of C3a and C5a receptor 1 (C3ar/C5ar1) pharmaceutical antagonistsin an in situ forming implant (ISFI) can robustly suppress such tumors. Antagonizing autocrine C3ar/C5ar1 signaling in eight human and murine cancers of diverse lineages was universally anti-mitotic and pro-apoptotic in vitro, and growth-repressive in vivo. In contrast to i.p. administration of C3ar/C5ar1 antagonists to tumor-bearing mice, injecting the antagonists intratumorally in slow release poly (lactic-co-glycolic acid) (PLGA) polymer caused near-complete tumor elimination. The focused blockade of C3ar/C5ar1 GPCR signaling in an intratumoral ISFI opposed solid cancers by jointly repressing cancer cell viability/growth, tumor-associated angiogenesis, and myeloid-derived suppressor cell (MDSC) recruitment. Thus, the sustained blockade of C3ar/C5ar1 signaling in an intratumoral ISFI uninterruptedly disrupts three processes essential for solid cancer growth while avoiding adverse effects on other cell types. Our findings may apply to multiple cancer types in which discrete tumor masses can be targeted.  \nKeywords: C5a; C5ar1 signaling; cancer viability  \n1. Introduction  \nAccumulating evidence has implicated the complement activation fragments C3a and C5a in modulating the growth of several cancer types [1–4] . C3a/C5a, traditionally presumed to derive from liver-produced complement components in plasma, are now regarded in some cases to also come from C3/C5 proteins produced by tumors or by immune and/or other cells in the tumor microenvironment (TME) . Some data point to the C3a/C5a functioning endogenously in the cells and in plasma [5–7] . Noncanonical effects on the tumor and/or on cells in the TME have been described [1–4] . The tumor modulatory functions of the C3a/C5a, however, remain incompletely characterized. Both tumor-suppressing and tumor-promoting effects of their blockade have been reported [8], limiting clinical translation.  \nWhile cytotoxic T effector cell (Teff) responses against tumors are able to evoke tumor inhibition or elimination in many cancers, many data have shown that myeloid-derived suppressor cells (MDSCs) in the TME characteristically subvert these Teff responses. Supplementing anti-cancer regimens with checkpoint inhibitors that can interdict the immuno-  \nsuppressive activities of the inhibitory cells has improved therapeutic outcomes, but some cancers still accumulate MDSCs and resist elimination. TME-associated C3a/C5a fragments have been implicated in contributing to this resistance.  \nRelevant to the currently known cellular functions ","cbCaij39SGheldUu","https://ap.wps.com/l/cbCaij39SGheldUu","pdf",6534824,17,"English","# Introduction\n# Materials and Methods\n## Reagents and Antibodies","[{\"question\":\"Why are solid tumors difficult to treat with CAR T cells or conventional therapies?\",\"answer\":\"Solid tumors typically expand within a “cold” immunosuppressive tumor microenvironment (TME), which resists killing by CAR T cells or conventional therapy.\"},{\"question\":\"What is the main therapeutic strategy tested in the study?\",\"answer\":\"The study tests intratumoral injection of C3ar/C5ar1 antagonists delivered via an in situ forming implant (ISFI), aiming for sustained blockade in the tumor and TME.\"},{\"question\":\"What biological processes are affected by intratumoral C3ar/C5ar1 blockade?\",\"answer\":\"The focused blockade disrupts solid cancer growth by jointly repressing cancer cell viability and growth, tumor-associated angiogenesis, and myeloid-derived suppressor cell (MDSC) recruitment.\"}]","Intratumoral C3ar/C5ar1 Antagonists Imbedded in an In Situ Forming Implant Can Robustly Suppress Solid Tumors | PDF",1790088961,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35faf8e5533c49c7a31b7e585128bf3c.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/166fe4d05bf07bc50dfdec1d120996a5.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5b7de89ad95079fb3b656bf698ac86d.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/345e5eb0b914c9d452b6d03dbef1d309.webp",980,1385]